Progress in Cardiovascular Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Anticoagulation Beyond 3 to 6Months: What Does the Data Tell Us?
Patients with a history of deep vein thrombosis and pulmonary embolism are at risk for a recurrent event. This is particularly true of patients with idiopathic events or events related to low risk triggers. In these patients extending anticoagulation beyond 3 to 6months may be warranted. Using clinical risk, biomarker analysis and risk stratification protocols we can make the best recommendations to patients with respect to the risks and benefits of ongoing therapy. Trials demonstrating benefit from low-dose aspirin for secondary prophylaxis may provide an option for patients in whom ongoing anticoagulation is deemed unsaf...
Source: Progress in Cardiovascular Diseases - April 7, 2018 Category: Cardiology Authors: Teresa L. Carman Source Type: research

Anticoagulation Beyond 3 to 6  Months: What Does the Data Tell Us?
Patients with a history of deep vein thrombosis and pulmonary embolism are at risk for a recurrent event. This is particularly true of patients with idiopathic events or events related to low risk triggers. In these patients extending anticoagulation beyond 3 to 6  months may be warranted. Using clinical risk, biomarker analysis and risk stratification protocols we can make the best recommendations to patients with respect to the risks and benefits of ongoing therapy. Trials demonstrating benefit from low-dose aspirin for secondary prophylaxis may provide a n option for patients in whom ongoing anticoagulation is deemed ...
Source: Progress in Cardiovascular Diseases - April 7, 2018 Category: Cardiology Authors: Teresa L. Carman Source Type: research

Spontaneous Coronary Artery Dissection: Cardiac Manifestations of Vascular Disease
Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndrome (ACS) in young women who otherwise do not have traditional risk factors for coronary artery disease. Though previously considered to be a rare occurrence and primarily associated with pregnancy, contemporary series have demonstrated that SCAD may account for 35% of ACS in women under the age of 50  years, and peripartum SCAD accounts for the minority of cases. Importantly, an association between SCAD and arterial abnormalities in non-coronary arterial distributions has been described. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - April 6, 2018 Category: Cardiology Authors: Vineet Agrawal, Esther S.H. Kim Source Type: research

Introduction to the Vascular Medicine Issue of Progress in Cardiovascular Diseases
This focused issue of Progress in Cardiovascular Diseases comes at a time in Vascular Medicine where there has been a veritable explosion in the science and care of the patient with vascular disease. The cardiovascular (CV) medicine physician would be remiss to not inform him or herself of the recent advances in vascular care, ranging from new clinical trials of the direct oral anticoagulants (DOACs) for the treatment of venous thromboembolism (VTE) to updated guidelines on the care of the patient with peripheral artery disease (PAD). (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - April 6, 2018 Category: Cardiology Authors: Esther S.H. Kim, Joshua A. Beckman Source Type: research

Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review
The potential cardiovascular (CV) disease (CVD) benefits of Omega-3 Polyunsaturated Fatty Acids (OM3) have been intensely studied and debated for decades. Initial trials were performed in patients with low use of maximal medical therapy for CVD, and reported significant mortality benefits with the use of 1  g/day OM3 intervention following myocardial infarction (MI). More recent studies, including cohorts of patients receiving modern guideline directed medical therapy for CVD, have often not shown similar benefits with OM3 use. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - March 20, 2018 Category: Cardiology Authors: Andrew Elagizi, Carl J. Lavie, Keri Marshall, James J. DiNicolantonio, James H. O'Keefe, Richard V. Milani Source Type: research

Combined Effect of Sauna Bathing and Cardiorespiratory Fitness on the Risk of Sudden Cardiac Deaths in Caucasian Men: A Long-term Prospective Cohort Study
Both cardiorespiratory fitness (CRF) and frequency of sauna bathing (FSB) are each strongly and independently associated with sudden cardiac death (SCD) risk. However, the combined effect of CRF and FSB on SCD risk has not been previously investigated. We evaluated the joint impact of CRF and FSB on the risk of SCD in the Kuopio Ischemic Heart Disease prospective cohort study of 2291 men aged 42 –61 years at recruitment. Objectively measured CRF and self-reported sauna bathing habits were assessed at baseline. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - March 15, 2018 Category: Cardiology Authors: Jari A. Laukkanen, Tanjaniina Laukkanen, Hassan Khan, Maira Babar, Setor K. Kunutsor Source Type: research

Combined Effect of Sauna Bathing and Cardiorespiratory Fitness on the Risk of Sudden Cardiac Deaths in Caucasian Men: a Long-Term Prospective Cohort Study
Both cardiorespiratory fitness (CRF) and frequency of sauna bathing (FSB) are each strongly and independently associated with sudden cardiac death (SCD) risk. However, the combined effect of CRF and FSB on SCD risk has not been previously investigated. We evaluated the joint impact of CRF and FSB on the risk of SCD in the Kuopio Ischemic Heart Disease prospective cohort study of 2291 men aged 42 –61 years at recruitment. Objectively measured CRF and self-reported sauna bathing habits were assessed at baseline. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - March 15, 2018 Category: Cardiology Authors: Jari A. Laukkanen, Tanjaniina Laukkanen, Hassan Khan, Maira Babar, Setor K. Kunutsor Source Type: research

Cutaneous Manifestations of Chronic Vascular Disease
In the contemporary era of medical diagnosis via sophisticated radiographic imaging and/or comprehensive serological testing, a focused physical examination remains paramount in recognizing the cutaneous manifestations of chronic vascular disease. Recognition of the unique cutaneous signs of lymphatic and venous hypertension assists in the diagnosis as well as the staging and classification of both lymphedema and chronic venous insufficiency. Awareness of explicit dermatologic vasomotor manifestations aids not only in the identification of acrocyanosis, Raynaud phenomenon, pernio, and erythromelalgia but also mitigates con...
Source: Progress in Cardiovascular Diseases - March 10, 2018 Category: Cardiology Authors: Steven M. Dean Source Type: research

Next Generation Endovascular Therapies in Peripheral Artery Disease
Endovascular therapy (EVT) of symptomatic peripheral artery disease (PAD) offers relief of symptoms and enhanced quality of life. Advancements in technique and technology have increased the feasibility and practicality of EVT, which now represents the preferred mode of revascularization over surgical procedures in many centers across the world. In this review, we consider the future of EVT in context of a rapidly expanding population of patients with symptomatic PAD. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - March 10, 2018 Category: Cardiology Authors: Matthew C. Bunte, Mehdi H. Shishehbor Source Type: research

Peri-Procedural Management of Oral Anticoagulants in the DOAC Era
Peri-procedural management of oral anticoagulants can be complex and confusing for many providers. It involves a careful balance of a patient's thromboembolic risk and bleeding risk. For every patient chronically taking an oral anticoagulant who will be undergoing an elective procedure, a four step approach may be considered when creating a plan for the oral anticoagulant. (1) Does the oral anticoagulant need to stop for the procedure? (2) If yes, when should the oral anticoagulant be stopped pre-procedure? (3) Does the patient require a “bridging” parenteral anticoagulant? (4) When should anticoagulation be re-started...
Source: Progress in Cardiovascular Diseases - March 10, 2018 Category: Cardiology Authors: Geoffrey D. Barnes, Erin Mouland Source Type: research

Fibromuscular Dysplasia: Contemporary Concepts and Future Directions
Fibromuscular dyplasia (FMD) is an under-recognized non-atherosclerotic, non-inflammatory arteriopathy that occurs most commonly in middle-aged women, but may affect individuals of all age groups. FMD may result in stenosis, aneurysm, dissection, occlusion, or arterial tortuosity. Recently published data demonstrated a genetic association of FMD with a variant in the phosphatase and actin regulator 1 gene (PHACTR1), substantiating that the pathogenesis of this condition has genetic contribution. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - March 10, 2018 Category: Cardiology Authors: Nupoor Narula, Daniella Kadian-Dodov, Jeffrey W. Olin Source Type: research